Patricia Silva, PhD, director of science content —

PatrĆ­cia holds a PhD in medical microbiology and infectious diseases from the Leiden University Medical Center, Netherlands, and completed a postdoctoral research fellowship at the Instituto de Medicina Molecular, Lisbon, Portugal. Her work in academia was mainly focused on molecular biology and the genetic traits of infectious agents such as viruses and parasites. PatrĆ­cia earned several travel awards to present her work at international scientific meetings. She is a published author of several peer-reviewed science articles.

Articles by Patricia Silva

Researcher Recommends Brain Imaging To Treat MS-Related Depression

Magnetic resonance imaging (MRI) can predict responses to depression treatment in patients with multiple sclerosis (MS), according to Anthony Feinstein, Professor at the Department of Psychiatry of the Sunnybrook Health Sciences Centre & the University of Toronto. In the presentation ā€œDepression in MS: Is brain imaging helpful?ā€ at this…

Multiple Sclerosis Drug NerventraĀ® (Laquinimod) Disapproved in EU; Drug Developers Will Continue Research

Two pharmaceutical companies,Ā Teva Pharmaceutical Industries Ltd. (TEVA) and Active Biotech, have just confirmed reports that theĀ Committee for Medicinal Products for Human Use (CHMP) is not recommendingĀ NERVENTRA (laquinimod) for use in treatingĀ relapsing-remitting multiple sclerosis (RRMS) within the European Union (EU), according to a recent press release. Despite CHMP’s disapproval of TEVA…

Newly Acquired Patents For Multiple Sclerosis, Alzheimer’s DNA Therapies Spurs New Clinical Trials At Inovio

Inovio Pharmaceuticals, a drug development company working on treatments that modulate therapeutically important immune responses with the help of T-cells, recently acquired the worldwide rights (apart from China), to conduct pre-clinical studies to produce products for possible therapies to treat and manage Alzheimer’s Disease (AD) and Multiple Sclerosis (MS).

New Secondary Progressive MS Drug Trial Completes Enrollment

Opexa Therapeutics, Inc., a drug delivery company based in The Woodlands, Texas, has been making significant progress in researching and developing TcelnaĀ®,Ā aĀ breakthrough T-cell immunotherapyĀ for multiple sclerosis (MS). The company recently announced they have reached their enrollment mark for conducting a Phase IIb clinical trial to testĀ Tcelna as a viable…